Business Overview / Sources of Revenue

Niagen Bioscience (NASDAQ: NAGE), formerly ChromaDex, is a bioscience company pioneering NAD+ research for healthy aging, centered on its patented ingredient **Niagen® (nicotinamide riboside, NR)**.[1][2][3]

It earns revenue by discovering, developing, and commercializing proprietary technologies for dietary supplements, food, beverages, skin care, and pharmaceuticals, via brands like **Tru Niagen®** (oral supplements) and **Niagen® Plus** (IV/injectable formulations).[2][3]

No percentage breakdown of revenue sources is available in current data.[1][2][3]

Revenue Growth Potential and Recurrence

**Niagen Bioscience (NAGE) lacks evidence of a large share of recurring revenue**, as search results provide no business segmentation on subscription models, repeat customers, or recurring streams despite strong Niagen® sales (77% of Q3 2025 revenue).[1][2][4]

**Revenue growth potential over 5+ years appears strong**, fueled by 36% YTD 2025 growth, e-commerce (56% of sales, +29%), B2B doublings, and partnerships; full-year 2025 guidance raised to **25-30% YoY** (from 20-25%).[1][2] Historical CAGR ~13% (2020-2024: $59M-$100M), accelerating to 38% Q1/37% Q4 2024 and 33% Q3 2025, supports sustained expansion via R&D, clinics, and NAD+ demand, though pharma-grade volatility persists.[1][2] Zacks implies ~21% net margins long-term.[3]

(98 words)

Economic Moat Factors

**Niagen Bioscience (NAGE) possesses a **moderate economic moat**, primarily from its **patented Niagen® (nicotinamide riboside, NR)**, a clinically proven NAD+ precursor backed by 35-40 trials, positioning it as the market leader in healthy-aging supplements.[1][2][4][5]**

**Key moat factors** include:
- **Unique assets & IP**: Robust patents protect NR across consumer (Tru Niagen, #1 U.S. NAD booster), IV/injectable (Niagen Plus), and pharma-grade products; first to offer branded ingredient in both DTC and prescription formats.[2][4]
- **Brand power & scale**: 25+ year legacy, #1 market position, strong gross margins (64%), and e-commerce growth create switching costs via proven efficacy and clinician adoption (475 clinics).[1][2][3]
- **Limited network effects**: No strong ones evident.

**Weaknesses**: NAD+ space faces competition from unpatented precursors, diluting exclusivity. Overall, patents and research leadership provide defensibility amid revenue growth (19% YoY).[1][2] (98 words)

Leadership

**Niagen Bioscience (NAGE) leadership** is led by **CEO Rob Fried** (aka Robert Fried), appointed June 2018 (7.6-year tenure as of 2026), not a founder (co-founder Frank Jaksch Jr. is Board Chairman).[1][4][6] Fried owns **2.1%** of shares (~$10.3M value) and earns $1.2M total comp (41% salary, 59% bonuses/stock).[4] Management avg. tenure: 5.9 years; strong science team includes SVP Andrew Shao, Ph.D.; Board (8.7-yr avg.) features Nobel laureate Roger Kornberg.[1][2][4] (78 words)

Financial Health

**Niagen Bioscience (NAGE) has strong financial health**, with a flawless balance sheet, high profitability (15.24% net margins, 23.12% ROE), and $116.3M annual sales, despite TradeSmith's "Red zone" rating.[1][2] **Yes, its balance sheet is healthy**: current ratio of 3.88 and quick ratio of 3.24 indicate ample liquidity with no reported debt (debt-to-equity N/A).[1] Free cash flow and margin data unavailable in sources. **Net repurchaser**: $10M share buyback authorized through 2027.[2] (78 words)

Last updated Jan 12, 2026